Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Liver Neoplasms 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Sorafenib 7Radiosurgery 6Bevacizumab 6pembrolizumab 4Oxaliplatin 4Cryosurgery 4atezolizumab 3Radiotherapy, Conformal 3Nivolumab 3Ipilimumab 3Fluorouracil 3Cyclophosphamide 3tremelimumab 2spartalizumab 2lenvatinib 2fludarabine 2Leucovorin 2Injections 2Gemcitabine 2Everolimus 2Epirubicin 2Doxorubicin 2Celecoxib 2Carboplatin 2Capecitabine 2yttrium chloride 1vofatamab 1toripalimab 1tocilizumab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liver Neoplasms × carotuximab × Clear all
NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡